HER2 pan-cancer species use the finger can wait for the next city of pyridine.

The new drug her1, HER2 and HER4 tyrosine kinase irreversible oral inhibitors developed in China have been approved in 2018 for the treatment of HER2-positive advanced breast cancerThis year ASCO's PHOEBEIII period data evidence that the pholateni scaperabin is superior to lapatini and Capethabin, and its position in breast cancer treatment has been greatly improvedThe HER2 mutation is also one of the most common driving mutation genes for lung cancer, with the insertion of an exon 20 most commonlySo far, the clinical treatment for patients with HER2 mutation lung adenocarcinoma is mainly chemotherapy, but overall, lung adenocarcinoma with HER2 mutation has a poor response to chemotherapy, and the overall survival rate of patients is difficult to be effectively improvedCurrently, some conventional anti-HER2 targeted drugs have not shown ideal efficacy in studies of HER2 mutation lung adenocarcinoma, and their toxic side effects can lead to intolerable rashes and diarrhea in patientsTherefore, in practical clinical applications, these drugs may not reach an effective treatment dose, resulting in poor treatment resultsThe national drug regulatory agency (NMPA) approved for the treatment of HER2-positive breast cancer targeted drugsAs a result, the researchers speculate that it may also have better results against NSCLC (lung adenocarcinoma) with her2 mutationsTo test this hypothesis, the researchers first conducted a cytological experiment that found better anti-tumor effect on HER2 mutation NSCLC than afatinib and T-DM1Therefore, a multi-center phase II clinical study was conducted to treat the HER2 mutation NSCLC with pyrith, mainly for patients with HER2 mutation NSCLC who failed chemotherapyGive the above patients 400 mg orally for treatment above the second lineStudies have shown that the ORR was 31.7% in patients and 6.8 months of PFSMoreover, oral pyridine has good safety, and the common adverse reactions in NSCLC patients are tolerable digestive symptoms such as diarrhea and vomitingThe results are reported at the 2019 ASCO Annual MeetingRecently, the JCO journal also published a study of pyridine treatment of the late STAGE NSCLC of her2 mutationResults are still brilliant, after breast cancer, and then take lung cancer, the strength of the practice of the use of good medicine pan-cancer species conceptThe study is an open-label, one-arm phase II clinical study that involved HER2 exon 20 mutations (confirmed by the center laboratory) and patients with iii-B and IV NSCLC patients who have previously received at least one platinum-containing chemotherapy to explore the efficacy and safety of pyritudininininininin in this population From October 20, 2016 to December 10, 2018, a total of 60 patients with HER2 mutation NSCLC were included, of which 96.7% (58) were patients with stage IV and 41.7% (25) had received 2 or more treatment regimens The patients in the group were treated with pyrith (400 mg, once daily) until the disease progression, intolerable toxicity, or withdrawal of informed consent The main study endpoints were Objective Mitigation Rate (ORR), and secondary studies included safety, progression-free survival (PFS), duration of disease progression (TTP), duration of mitigation (DoR), and total lifetime (OS) Results As of June 20, 2019, the results show that: (1) efficiency, overall efficiency ORR is 30%, all partially alleviated, 55.0% of patients are stable, disease control rate is 85%, 21.7% of patients show disease stability for at least 24 weeks Of the 18 people who recorded reactions, 33.3% had a sustained response, with a median DOR of 6.9 months (95% CI, 4.9-11.1) (2) PFS and OS to data cut-off date, 65.0% of patients showed no progression survival, median PFS was 6.9 months (95% CI, 5.5 to 8.3 months) The 12-month PFS rate was 22.5% (95% CI, 10.8% to 36.8%) On the data deadline, 50.0% of patients died; The 12-month OS rate was 69.1% (95% CI, 55.0% to 79.6%) (3) The efficiency of different HER2 mutant subtypes In patients of different mutation types, 44 patients with 20 exosome insertion mutations had ANRs of 27.3% and 6 patients with G776 mutation genes had ANRs of 16.7%, 5 The ORR was 60.0% in patients with 20 exosome 9bp insertion mutations, 1 patient with V777L mutation had an ORR of 100%, and 4 patients with L755P mutation had an ORR of 25.0% (4) The efficacy of pyridine on brain transfer patients was similar in patients with no brain transfer at baseline, with 25.0% v 31.3%, and the median PFS for 5.5 months v 6.9 months The ORR was 44.0% in patients who had previously received at least 2 line of chemotherapy, a 20.0% larger figure than those who had undergone first line of chemotherapy (5) Safety In the median 10 treatment cycles, any level of treatment-related adverse reactions were reported in 98.3% of patients, most of which were level 1 or 2 adverse reactions The most common therapeutic-related adverse reactions were diarrhea (91.7%), increased blood creatinine (30.0%), and vomiting (28.3%) Diarrhea above level 3 is 20% As an innovative drug in China's original research, the oxycodone has been the focus of attention since its birth, and it has been surprising to the Chinese people with outstanding performance: by virtue of its achievements in the treatment of HER2-positive breast cancer, previously, the oxycodone has been published twice in JCO magazine, twice selected as an ASCO oral report In the field of HER2 mutant advanced lung cancer, the her2 mutation of advanced lung cancer, has "completed" the domestic listed imported drugs, HER2 pan-cancer species use is within reach We also look forward to the success of the stage III clinical study of advanced lung cancer of HER2 mutationinins in the near future, the success of lung cancer indications, for patients to solve the urgent problem, not only for the benefit of Chinese patients, but also to the world's patients to share the well-being of China's "intellectual" creation Source: 1.Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based: A Multicenter, Open-Label, Single-Arm, Phase II Study; 2.2019ASCO: Abstract 9089 Original title: Research and Development The next city of pyridine - lung cancer, HER2 pan-cancer species use is within reach.